Rep. Jared Moskowitz Unloads Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Representative Jared Moskowitz (D-Florida) recently sold shares of West Pharmaceutical Services, Inc. (NYSE:WST). In a filing disclosed on December 09th, the Representative disclosed that they had sold between $1,001 and $15,000 in West Pharmaceutical Services stock on November 8th. The trade occurred in the Representative’s “MORGAN STANLEY ACTIVE ASSETS (1)” account.

Representative Jared Moskowitz also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Atmos Energy (NYSE:ATO) on 11/8/2024.
• Purchased $1,001 – $15,000 in shares of Elevance Health (NYSE:ELV) on 11/8/2024.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 11/8/2024.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 11/8/2024.
• Purchased $1,001 – $15,000 in shares of QUALCOMM (NASDAQ:QCOM) on 11/8/2024.
• Purchased $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 11/8/2024.
• Purchased $1,001 – $15,000 in shares of Tractor Supply (NASDAQ:TSCO) on 11/8/2024.
• Purchased $1,001 – $15,000 in shares of McDonald’s (NYSE:MCD) on 11/8/2024.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOG) on 11/8/2024.
• Sold $50,001 – $100,000 in shares of Seacoast Banking Co. of Florida (NASDAQ:SBCF) on 11/8/2024.

West Pharmaceutical Services Stock Performance

Shares of WST opened at $318.04 on Thursday. The firm has a market capitalization of $23.03 billion, a P/E ratio of 47.19, a P/E/G ratio of 24.47 and a beta of 1.01. West Pharmaceutical Services, Inc. has a 52 week low of $265.00 and a 52 week high of $413.70. The stock has a 50 day moving average price of $311.37 and a two-hundred day moving average price of $311.71. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.23 and a current ratio of 3.00.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, October 24th. The medical instruments supplier reported $1.85 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.35. The firm had revenue of $746.90 million for the quarter, compared to the consensus estimate of $709.62 million. West Pharmaceutical Services had a return on equity of 18.41% and a net margin of 17.37%. The company’s revenue was down .1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.16 EPS. Equities analysts forecast that West Pharmaceutical Services, Inc. will post 6.64 earnings per share for the current fiscal year.

West Pharmaceutical Services Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 20th. Shareholders of record on Wednesday, November 13th were paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.26%. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.20. The ex-dividend date was Wednesday, November 13th. West Pharmaceutical Services’s dividend payout ratio (DPR) is 12.46%.

Insiders Place Their Bets

In related news, VP Charles Witherspoon sold 703 shares of the business’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $310.40, for a total transaction of $218,211.20. Following the transaction, the vice president now owns 1,253 shares in the company, valued at $388,931.20. The trade was a 35.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.53% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Crewe Advisors LLC raised its holdings in shares of West Pharmaceutical Services by 322.7% during the 2nd quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 71 shares in the last quarter. Northwest Investment Counselors LLC bought a new stake in shares of West Pharmaceutical Services in the 3rd quarter worth approximately $30,000. Brooklyn Investment Group purchased a new stake in shares of West Pharmaceutical Services in the 3rd quarter valued at $41,000. Quest Partners LLC grew its holdings in shares of West Pharmaceutical Services by 5,633.3% during the 2nd quarter. Quest Partners LLC now owns 172 shares of the medical instruments supplier’s stock valued at $57,000 after purchasing an additional 169 shares during the last quarter. Finally, Blue Trust Inc. raised its position in West Pharmaceutical Services by 332.1% in the 2nd quarter. Blue Trust Inc. now owns 242 shares of the medical instruments supplier’s stock worth $80,000 after purchasing an additional 186 shares during the period. Hedge funds and other institutional investors own 93.90% of the company’s stock.

About Representative Moskowitz

Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida’s 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2025. Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida’s 23rd Congressional District. He declared candidacy for the Democratic primary scheduled on August 20, 2024. Moskowitz resigned his state House seat on January 11, 2019, to head the state’s Division of Emergency Management. Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor’s degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz’s career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.